Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$716 Mln
P/E Ratio
97.81
P/B Ratio
3.77
Industry P/E
87.38
Debt to Equity
0
ROE
0.04 %
ROCE
--
Div. Yield
0.68 %
Book Value
--
EPS
--
CFO
$122.67 Mln
EBITDA
$107.29 Mln
Net Profit
$80.53 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Simulations Plus (SLP)
| 25.71 | 44.34 | 3.15 | -21.55 | -10.28 | -2.91 | 19.67 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Simulations Plus (SLP)
| -37.44 | 22.37 | -22.68 | -34.23 | 147.40 | 46.08 | 23.46 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 9.58 | 391.45 | -- | -21.65 | |
| 3.61 | 9.78 | -- | -89.15 | |
| 5.03 | 1,128.60 | -- | -16.75 |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates... through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California. Address: 42505 Tenth Street West, Lancaster, CA, United States, 93534-7059 Read more
Co-Founder & Chairman
Dr. Walter S. Woltosz M.A.S., M.S.
Co-Founder & Chairman
Dr. Walter S. Woltosz M.A.S., M.S.
Headquarters
Lancaster, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Simulations Plus Inc (SLP) stood at $ 212 Mln as on 28-Feb-25
The share price of Simulations Plus Inc (SLP) is $35.06 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Simulations Plus Inc (SLP) has given a return of -10.28% in the last 3 years.
Simulations Plus Inc (SLP) has a market capitalisation of $ 716 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Simulations Plus Inc (SLP) is 3.77 times as on 29-Apr-2025, a 5% premium to its peers’ median range of 3.59 times.
The P/E ratio of Simulations Plus Inc (SLP) is 97.81 times as on 29-Apr-2025, a 12% premium to its peers’ median range of 87.38 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Simulations Plus Inc (SLP) and enter the required number of quantities and click on buy to purchase the shares of Simulations Plus Inc (SLP).
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California. Address: 42505 Tenth Street West, Lancaster, CA, United States, 93534-7059
The CEO & director of Dr. Walter S. Woltosz M.A.S., M.S.. is Simulations Plus Inc (SLP), and CFO & Sr. VP is Dr. Walter S. Woltosz M.A.S., M.S..
There is no promoter pledging in Simulations Plus Inc (SLP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
95
|
|
|
38
|
|
|
1
|
|
|
95
|
| Simulations Plus Inc. (SLP) | Ratios |
|---|---|
|
Return on equity(%)
|
3.88
|
|
Operating margin(%)
|
0.93
|
|
Net Margin(%)
|
9.19
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Simulations Plus Inc (SLP) was $0 Mln.
$-0.15
(
